123 related articles for article (PubMed ID: 18502195)
1. Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis.
Boutin JA; Saunier C; Guenin SP; Berger S; Moulharat N; Gohier A; Delagrange P; Cogé F; Ferry G
Arch Biochem Biophys; 2008 Sep; 477(1):12-9. PubMed ID: 18502195
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.
Mailliet F; Ferry G; Vella F; Berger S; Cogé F; Chomarat P; Mallet C; Guénin SP; Guillaumet G; Viaud-Massuard MC; Yous S; Delagrange P; Boutin JA
Biochem Pharmacol; 2005 Dec; 71(1-2):74-88. PubMed ID: 16293234
[TBL] [Abstract][Full Text] [Related]
3. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate.
Boutin JA; Marcheteau E; Hennig P; Moulharat N; Berger S; Delagrange P; Bouchet JP; Ferry G
J Pineal Res; 2008 Nov; 45(4):524-31. PubMed ID: 18826489
[TBL] [Abstract][Full Text] [Related]
4. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3.
Mailliet F; Ferry G; Vella F; Thiam K; Delagrange P; Boutin JA
FEBS Lett; 2004 Dec; 578(1-2):116-20. PubMed ID: 15581627
[TBL] [Abstract][Full Text] [Related]
5. NRH:quinone reductase 2: an enzyme of surprises and mysteries.
Vella F; Ferry G; Delagrange P; Boutin JA
Biochem Pharmacol; 2005 Dec; 71(1-2):1-12. PubMed ID: 16253210
[TBL] [Abstract][Full Text] [Related]
6. New ligands at the melatonin binding site MT(3).
Boussard MF; Truche S; Rousseau-Rojas A; Briss S; Descamps S; Droual M; Wierzbicki M; Ferry G; Audinot V; Delagrange P; Boutin JA
Eur J Med Chem; 2006 Mar; 41(3):306-20. PubMed ID: 16414149
[TBL] [Abstract][Full Text] [Related]
7. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance.
Tan DX; Manchester LC; Terron MP; Flores LJ; Tamura H; Reiter RJ
J Pineal Res; 2007 Nov; 43(4):317-20. PubMed ID: 17910598
[TBL] [Abstract][Full Text] [Related]
8. X-ray structural studies of quinone reductase 2 nanomolar range inhibitors.
Pegan SD; Sturdy M; Ferry G; Delagrange P; Boutin JA; Mesecar AD
Protein Sci; 2011 Jul; 20(7):1182-95. PubMed ID: 21538647
[TBL] [Abstract][Full Text] [Related]
9. Quinone reductase 2 and antidepressant effect of melatonin derivatives.
Oxenkrug GF; Bachurin SO; Prakhie IV; Zefirov NS
Ann N Y Acad Sci; 2010 Jun; 1199():121-4. PubMed ID: 20633117
[TBL] [Abstract][Full Text] [Related]
10. The role of proline residues in the structure and function of human MT2 melatonin receptor.
Mazna P; Grycova L; Balik A; Zemkova H; Friedlova E; Obsilova V; Obsil T; Teisinger J
J Pineal Res; 2008 Nov; 45(4):361-72. PubMed ID: 18544139
[TBL] [Abstract][Full Text] [Related]
11. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.
Calamini B; Santarsiero BD; Boutin JA; Mesecar AD
Biochem J; 2008 Jul; 413(1):81-91. PubMed ID: 18254726
[TBL] [Abstract][Full Text] [Related]
12. The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor.
Kokkola T; Salo OM; Poso A; Laitinen JT
J Pineal Res; 2005 Aug; 39(1):1-11. PubMed ID: 15978051
[TBL] [Abstract][Full Text] [Related]
13. Old and new inhibitors of quinone reductase 2.
Ferry G; Hecht S; Berger S; Moulharat N; Coge F; Guillaumet G; Leclerc V; Yous S; Delagrange P; Boutin JA
Chem Biol Interact; 2010 Jul; 186(2):103-9. PubMed ID: 20399199
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .
Nosjean O; Nicolas JP; Klupsch F; Delagrange P; Canet E; Boutin JA
Biochem Pharmacol; 2001 Jun; 61(11):1369-79. PubMed ID: 11331072
[TBL] [Abstract][Full Text] [Related]
16. [Melatonin binding site MT3 is QR2: state of the art].
Boutin JA
J Soc Biol; 2007; 201(1):97-103. PubMed ID: 17762829
[TBL] [Abstract][Full Text] [Related]
17. Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7.
Mazna P; Berka K; Jelinkova I; Balik A; Svoboda P; Obsilova V; Obsil T; Teisinger J
Biochem Biophys Res Commun; 2005 Jul; 332(3):726-34. PubMed ID: 15913560
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of melatonin ligands.
Delagrange P; Boutin JA
Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
[TBL] [Abstract][Full Text] [Related]
19. Insights into the redox cycle of human quinone reductase 2.
Reybier K; Perio P; Ferry G; Bouajila J; Delagrange P; Boutin JA; Nepveu F
Free Radic Res; 2011 Oct; 45(10):1184-95. PubMed ID: 21762045
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
